GO
Loading...

Cramer’s One-on-One with Immunogen CEO

Monday, 4 Jun 2012 | 6:20 PM ET

Despite today's tough market environment, there are still some stocks speculating on, said Jim Cramer on CNBC’s “Mad Money.”

“If anything, the pervasive sense of fear and pessimism is creating opportunities,” Cramer explained. “You just need to know where to look.”

Take ImmunoGen, for example. Cramer has long liked this speculative biotechnology company, which develops next generation cancer treatments. Its technology allows cancer drugs to target and kill cancer cells while leaving the rest of the body mostly unharmed. At the American Society of Clinical Oncology’s annual meeting on Monday, the company released bullish data on two drugs it’s working on, including T-DM1, a breast cancer drug that it’s developing with , as well as a non-Hodgkin’s lymphoma drug that Sanofi’s developing by using ImmunoGen’s technology.

ImmunoGen CEO on Competitive Cancer Drug Landscape
Daniel Junius, ImmunoGen chairman/CEO, discusses the latest developments in therapeutics for the treatment of cancer.

To learn more about the data and the company’s prospects in general, Cramer interviewed ImmunoGen CEO Daniel Junius. Watch the video of the full interview.

Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

  Price   Change %Change
IMGN
---
SNI
---

Contact Mad Money

  • Showtimes

    Monday - Friday 6p ET
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.